ReviewKidney international reports2024
Updates on New Therapies for Patients with CKD.
Review in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The Effect of Empagliflozin on Renal Outcomes in Patients With Established Cardiovascular Disease: Systematic Review and Meta-Analysis of Randomised Placebo-Controlled Trials.Endocrinology, diabetes & metabolism · 2026Pooled it
- Cardiometabolic index (CMI) and sarcopenia as predictors of all-cause and cardiovascular mortality in chronic kidney disease: a NHANES-based cohort study.Renal failure · 2026Article
- Disulfiram Attenuates Adenine-Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- The role of protein prenylation in kidney diseases: Molecular basis and therapeutic implications.Molecular biology reports · 2026Review
- SIRT6 Attenuates Angiotensin II-Induced Podocyte Cholesterol Accumulation and Injury via Negative Modulation of SREBP2.Kidney & blood pressure research · 2026Article
- Article
- Frequent hypoglycemia during hemodialysis in ESRD patients leads to higher risk of death.Renal failure · 2025Article
- CKDs at the Crossroads: From Failures to Future Therapies.Kidney international reports · 2025Review
- Effect of Spherical Adsorptive Carbon Among Chronic Kidney Disease Patients: A Nationwide Cohort Study.International journal of environmental research and public health · 2025Article
- Prognostic Implications of Diabetes Insipidus in Heart Failure Hospitalizations: Insights from the U.S. National Readmissions Database 2016-2021.Journal of clinical medicine · 2025Article
- Association between the aggregate index of systemic inflammation and CKD: evidence from NHANES 1999-2018.Frontiers in medicine · 2025Article
- Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess.Frontiers in pharmacology · 2025Article
- The Legacy Effect of Intensive versus Standard BP Control on the Incidence of Needing Dialysis or Kidney Transplantation.Journal of the American Society of Nephrology : JASN · 2024Article
- The Leicester, Leicestershire and Rutland quality improvement project and integrated chronic kidney disease system: implementation within a primary care network.BMC nephrology · 2024Article
- Challenging the Restrictive Approach: Reconsidering Sodium-Glucose Transport Protein 2 Inhibitor Use in CKD.Kidney international reports · 2024Article
- Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International journal of molecular sciences · 2024Review
- Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Individuals diagnosed with chronic kidney disease (CKD) continue to increase globally. This group of patients experience a disproportionately higher risk of cardiovascular (CV) events compared to the general population. Despite multiple guidelines-based medical management, patients with CKD continue to experience residual cardiorenal risk. Several potential mechanisms explain this excessive CV risk observed in individuals with CKD. Several new drugs have become available that could potentially transform CKD care, given their efficacy in this patient population. Nevertheless, use of these drugs presents certain benefits and challenges that are often underrecognized by prescribing these drugs. In this review, we aim to provide a brief discussion about CKD pathophysiology, limiting our discussion to recent published studies. We also explore benefits and limitations of newer drugs, including angiotensin receptor/neprilysin inhibitors (ARNI), sodium glucose transporter 2 inhibitors (SGLT2i), glucagon-like peptides-1 (GLP-1) agonists and finerenone in patients with CKD. Despite several articles covering this topic, our review provides an algorithm where subgroups of patients with CKD might benefit the most from such drugs based on the selection criteria of the landmark trials. Patients with CKD who have nephrotic range proteinuria beyond 5000 mg/g, or those with poorly controlled blood pressure (systolic ≥160 mm Hg or diastolic ≥100 mm Hg) remain understudied.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.